PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have
an advanced malignancy (cancer) or stage IV melanoma.